Jennifer Oliver
About
Jennifer Oliver is a scholar working on Oncology, Endocrinology, Diabetes and Metabolism and Pathology and Forensic Medicine.
According to data from OpenAlex, Jennifer Oliver has authored 31 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Jennifer Oliver's work include Thyroid Cancer Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Jennifer Oliver is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Jennifer Oliver collaborates with scholars based in United States, South Korea and Taiwan. Jennifer Oliver's co-authors include Richard L. Kravitz, Frederick J. Meyers, Sherrie H. Kaplan, Danielle Hessler, Jackie Sturt, Lawrence Fisher, Kathryn Dennick, Benjamin M. Hunter, Richard H. van der Jagt and Katherine Robinson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Jennifer Oliver
31 papers receiving 1.3k citations
Hit Papers
Peers
Jennifer Oliver
Richard Gregg Canada
Louise Bordeleau Canada
Alan Gray Saudi Arabia
Jean‐Claude Givel Switzerland
Abhishek Chatterjee United States
Eun‐Kee Song South Korea
Hiroto Narimatsu Japan
Giorgio Cruciani Italy
Rebecca Cowens-Alvarado United States
Hsien‐Kun Chang Taiwan
Citations per year, relative to Jennifer Oliver Jennifer Oliver (= 1×)
peers
Richard Gregg
Countries citing papers authored by Jennifer Oliver
Since
Specialization
Citations
This map shows the geographic impact of Jennifer Oliver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Oliver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Oliver more than expected).
Fields of papers citing papers by Jennifer Oliver
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jennifer Oliver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Oliver. The network helps show where Jennifer Oliver may publish in the future.
Co-authorship network of co-authors of Jennifer Oliver
This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Oliver. A scholar is included among the top collaborators of Jennifer Oliver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Oliver. Jennifer Oliver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Capdevila, Jaume, Jolanta Krajewska, Jorge Hernando, et al.. (2023). Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 34(3). 347–359.
2.
Brose, Marcia S., Bruce Robinson, Steven I. Sherman, et al.. (2021). Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 22(8). 1126–1138.
3.
Robinson, Bruce, Steven I. Sherman, Barbara Jarząb, et al.. (2021). LBA67 Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Updated results from the phase III COSMIC-311 trial and prespecified subgroup analyses by prior therapy. Annals of Oncology. 32. S1343–S1343.
4.
Brose, Marcia S., Bruce Robinson, Steven I. Sherman, et al.. (2021). Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial.. Journal of Clinical Oncology. 39(15_suppl). 6001–6001.
5.
Kelley, Robin Kate, Jennifer Oliver, Saswati Hazra, et al.. (2020). Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncology. 16(21). 1525–1536.
6.
Oliver, Jennifer, et al.. (2020). Transitioning to zero-emission bus fleets: state of practice of implementations in the United States. Transport Reviews. 41(2). 164–191.
7.
Drilon, Alexander, Stephen V. Liu, Robert C. Doebele, et al.. (2017). A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC. Annals of Oncology. 28. v612–v612.
8.
Somwar, Romel, James D. Joseph, Roger S. Smith, et al.. (2016). Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations. Clinical Cancer Research. 23(12). 2981–2990.
9.
Patel, Manish R., Marwan Fakih, Anthony J. Olszanski, et al.. (2016). A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology. 34(15_suppl). 2574–2574.
10.
Dennick, Kathryn, Jackie Sturt, Danielle Hessler, et al.. (2015). High rates of elevated diabetes distress in research populations: A systematic review and meta-analysis. ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam). 12(3). 93–107.
11.
Sturt, Jackie, Kathryn Dennick, Danielle Hessler, et al.. (2015). Effective interventions for reducing diabetes distress: systematic review and meta-analysis. Research Portal (King's College London). 12(2). 40–55.
12.
Chen, Mark, et al.. (2013). A new detection method for the onset of PCB pad cratering. 96–100.
13.
Kravitz, Richard L., Daniel J. Tancredi, Donna Kalauokalani, et al.. (2011). Cancer Health Empowerment for Living without Pain (Ca-HELP): effects of a tailored education and coaching intervention on pain and impairment. Pain. 152(7). 1572–1582.
14.
Jotte, Robert M., Paul Conkling, Craig H. Reynolds, et al.. (2010). Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy. Journal of Clinical Oncology. 29(3). 287–293.
15.
Ettinger, David S., Robert M. Jotte, Paul Lorigan, et al.. (2010). Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer. Journal of Clinical Oncology. 28(15). 2598–2603.
16.
Friedberg, Jonathan W., Philip Cohen, Ling Chen, et al.. (2008). Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study. Journal of Clinical Oncology. 26(2). 204–210.
17.
Kalauokalani, Donna, Peter Franks, Jennifer Oliver, Frederick J. Meyers, & Richard L. Kravitz. (2007). Can Patient Coaching Reduce Racial/Ethnic Disparities in Cancer Pain Control? Secondary Analysis of a Randomized Controlled Trial. Pain Medicine. 8(1). 17–24.
18.
Jagt, Richard H. van der, Philip Cohen, Bruce D. Cheson, et al.. (2006). Phase II Results of Bendamustine in Combination with Rituximab in Relapsed Indolent and Mantle-Cell Non-Hodgkin’s Lymphoma.. Blood. 108(11). 2710–2710.
19.
Robinson, Katherine, Michael E. Williams, Philip Cohen, et al.. (2005). Bendamustine HCl (TREANDATM) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).. Blood. 106(11). 923–923.
20.
Rao, Sheela, David Watkins, David Cunningham, et al.. (2004). Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. Annals of Oncology. 15(9). 1413–1418.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Richard Gregg Breakdown of academic impact, for papers by Louise Bordeleau Breakdown of academic impact, for papers by Alan Gray Breakdown of academic impact, for papers by Jean‐Claude Givel Breakdown of academic impact, for papers by Abhishek Chatterjee Breakdown of academic impact, for papers by Eun‐Kee Song Breakdown of academic impact, for papers by Hiroto Narimatsu Breakdown of academic impact, for papers by Giorgio Cruciani Breakdown of academic impact, for papers by Rebecca Cowens-Alvarado Breakdown of academic impact, for papers by Hsien‐Kun Chang